|
EP2734621B1
(en)
|
2011-07-22 |
2019-09-04 |
President and Fellows of Harvard College |
Evaluation and improvement of nuclease cleavage specificity
|
|
US9163284B2
(en)
|
2013-08-09 |
2015-10-20 |
President And Fellows Of Harvard College |
Methods for identifying a target site of a Cas9 nuclease
|
|
US9359599B2
(en)
|
2013-08-22 |
2016-06-07 |
President And Fellows Of Harvard College |
Engineered transcription activator-like effector (TALE) domains and uses thereof
|
|
US9322037B2
(en)
|
2013-09-06 |
2016-04-26 |
President And Fellows Of Harvard College |
Cas9-FokI fusion proteins and uses thereof
|
|
US9526784B2
(en)
|
2013-09-06 |
2016-12-27 |
President And Fellows Of Harvard College |
Delivery system for functional nucleases
|
|
US9340800B2
(en)
|
2013-09-06 |
2016-05-17 |
President And Fellows Of Harvard College |
Extended DNA-sensing GRNAS
|
|
US20150165054A1
(en)
|
2013-12-12 |
2015-06-18 |
President And Fellows Of Harvard College |
Methods for correcting caspase-9 point mutations
|
|
CA2956224A1
(en)
|
2014-07-30 |
2016-02-11 |
President And Fellows Of Harvard College |
Cas9 proteins including ligand-dependent inteins
|
|
BR112017017810A2
(pt)
|
2015-02-23 |
2018-04-10 |
Crispr Therapeutics Ag |
materiais e métodos para tratamento de hemoglobinopatias
|
|
US12129471B2
(en)
|
2015-02-23 |
2024-10-29 |
Vertex Pharmaceuticals Incorporated |
Materials and methods for treatment of human genetic diseases including hemoglobinopathies
|
|
CA2986310A1
(en)
|
2015-05-11 |
2016-11-17 |
Editas Medicine, Inc. |
Optimized crispr/cas9 systems and methods for gene editing in stem cells
|
|
WO2016201047A1
(en)
|
2015-06-09 |
2016-12-15 |
Editas Medicine, Inc. |
Crispr/cas-related methods and compositions for improving transplantation
|
|
EP4434589A3
(en)
|
2015-10-23 |
2025-05-14 |
President and Fellows of Harvard College |
Evolved cas9 proteins for gene editing
|
|
ES2942309T3
(es)
|
2015-11-04 |
2023-05-31 |
Vertex Pharma |
Materiales y métodos para el tratamiento de hemoglobinopatías
|
|
JP7231935B2
(ja)
|
2016-08-03 |
2023-03-08 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
アデノシン核酸塩基編集因子およびそれらの使用
|
|
US11661590B2
(en)
|
2016-08-09 |
2023-05-30 |
President And Fellows Of Harvard College |
Programmable CAS9-recombinase fusion proteins and uses thereof
|
|
WO2018039438A1
(en)
|
2016-08-24 |
2018-03-01 |
President And Fellows Of Harvard College |
Incorporation of unnatural amino acids into proteins using base editing
|
|
AU2017342543B2
(en)
|
2016-10-14 |
2024-06-27 |
President And Fellows Of Harvard College |
AAV delivery of nucleobase editors
|
|
LT3535392T
(lt)
*
|
2016-11-02 |
2024-04-25 |
Universität Basel |
Imunologiškai atpažįstami ląstelių paviršiaus variantai, skirti naudoti ląstelių terapijoje
|
|
WO2018119359A1
(en)
|
2016-12-23 |
2018-06-28 |
President And Fellows Of Harvard College |
Editing of ccr5 receptor gene to protect against hiv infection
|
|
TW201839136A
(zh)
*
|
2017-02-06 |
2018-11-01 |
瑞士商諾華公司 |
治療血色素異常症之組合物及方法
|
|
CN110662556A
(zh)
|
2017-03-09 |
2020-01-07 |
哈佛大学的校长及成员们 |
癌症疫苗
|
|
US11898179B2
(en)
|
2017-03-09 |
2024-02-13 |
President And Fellows Of Harvard College |
Suppression of pain by gene editing
|
|
JP2020510439A
(ja)
|
2017-03-10 |
2020-04-09 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
シトシンからグアニンへの塩基編集因子
|
|
WO2018170184A1
(en)
|
2017-03-14 |
2018-09-20 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
WO2018176009A1
(en)
|
2017-03-23 |
2018-09-27 |
President And Fellows Of Harvard College |
Nucleobase editors comprising nucleic acid programmable dna binding proteins
|
|
EP3615664A4
(en)
|
2017-04-24 |
2021-01-27 |
Seattle Children's Hospital (DBA Seattle Children's Research Institute) |
HOMOLOGY-DIRECTED REPAIR COMPOSITIONS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
|
|
WO2018209158A2
(en)
|
2017-05-10 |
2018-11-15 |
Editas Medicine, Inc. |
Crispr/rna-guided nuclease systems and methods
|
|
US11560566B2
(en)
|
2017-05-12 |
2023-01-24 |
President And Fellows Of Harvard College |
Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
|
|
EP3645721A1
(en)
*
|
2017-06-30 |
2020-05-06 |
Novartis AG |
Methods for the treatment of disease with gene editing systems
|
|
WO2019014564A1
(en)
|
2017-07-14 |
2019-01-17 |
Editas Medicine, Inc. |
SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
|
|
US11732274B2
(en)
|
2017-07-28 |
2023-08-22 |
President And Fellows Of Harvard College |
Methods and compositions for evolving base editors using phage-assisted continuous evolution (PACE)
|
|
WO2019139645A2
(en)
|
2017-08-30 |
2019-07-18 |
President And Fellows Of Harvard College |
High efficiency base editors comprising gam
|
|
KR20200121782A
(ko)
*
|
2017-10-16 |
2020-10-26 |
더 브로드 인스티튜트, 인코퍼레이티드 |
아데노신 염기 편집제의 용도
|
|
WO2019081982A1
(en)
*
|
2017-10-26 |
2019-05-02 |
Crispr Therapeutics Ag |
SUBSTANCES AND METHODS FOR THE TREATMENT OF HEMOGLOBINOPATHIES
|
|
CN111556893A
(zh)
*
|
2017-11-06 |
2020-08-18 |
爱迪塔斯医药股份有限公司 |
免疫疗法t细胞中cblb的crispr-cas9编辑的方法、组合物和组分
|
|
SG11202005147WA
(en)
|
2017-12-05 |
2020-06-29 |
Vertex Pharma |
Crispr-cas9 modified cd34+ human hematopoietic stem and progenitor cells and uses thereof
|
|
CN111712569A
(zh)
*
|
2017-12-11 |
2020-09-25 |
爱迪塔斯医药公司 |
用于基因编辑的Cpf1-相关方法和组合物
|
|
US12406749B2
(en)
|
2017-12-15 |
2025-09-02 |
The Broad Institute, Inc. |
Systems and methods for predicting repair outcomes in genetic engineering
|
|
WO2019150203A1
(en)
|
2018-02-05 |
2019-08-08 |
Crispr Therapeutics Ag |
Materials and methods for treatment of hemoglobinopathies
|
|
WO2019173654A2
(en)
*
|
2018-03-07 |
2019-09-12 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
EP3765617A1
(en)
*
|
2018-03-14 |
2021-01-20 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
EP3765614A1
(en)
*
|
2018-03-14 |
2021-01-20 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
CA3098382A1
(en)
*
|
2018-04-24 |
2019-10-31 |
Ligandal, Inc. |
Methods and compositions for genome editing
|
|
KR20250134703A
(ko)
*
|
2018-05-11 |
2025-09-11 |
빔 테라퓨틱스, 인크. |
프로그래밍가능한 염기 편집기 시스템을 이용하여 병원성 아미노산을 치환하는 방법
|
|
US12157760B2
(en)
|
2018-05-23 |
2024-12-03 |
The Broad Institute, Inc. |
Base editors and uses thereof
|
|
US12522807B2
(en)
|
2018-07-09 |
2026-01-13 |
The Broad Institute, Inc. |
RNA programmable epigenetic RNA modifiers and uses thereof
|
|
US20220033856A1
(en)
*
|
2018-09-11 |
2022-02-03 |
Université de Paris |
Methods for increasing fetal hemoglobin content in eukaryotic cells and uses thereof for the treatment of hemoglobinopathies
|
|
WO2020092453A1
(en)
|
2018-10-29 |
2020-05-07 |
The Broad Institute, Inc. |
Nucleobase editors comprising geocas9 and uses thereof
|
|
WO2020113112A1
(en)
*
|
2018-11-29 |
2020-06-04 |
Editas Medicine, Inc. |
Systems and methods for the treatment of hemoglobinopathies
|
|
AU2019392748A1
(en)
*
|
2018-12-05 |
2021-06-10 |
Fred Hutchinson Cancer Center |
Reduced and minimal manipulation manufacturing of genetically-modified cells
|
|
CN111321171A
(zh)
*
|
2018-12-14 |
2020-06-23 |
江苏集萃药康生物科技有限公司 |
一种应用CRISPR/Cas9介导ES打靶技术制备基因打靶动物模型的方法
|
|
WO2020154500A1
(en)
|
2019-01-23 |
2020-07-30 |
The Broad Institute, Inc. |
Supernegatively charged proteins and uses thereof
|
|
US20220235347A1
(en)
|
2019-02-13 |
2022-07-28 |
Beam Therapeutics Inc. |
Compositions and methods for treating hemoglobinopathies
|
|
MX2021011426A
(es)
|
2019-03-19 |
2022-03-11 |
Broad Inst Inc |
Metodos y composiciones para editar secuencias de nucleótidos.
|
|
WO2020214842A1
(en)
|
2019-04-17 |
2020-10-22 |
The Broad Institute, Inc. |
Adenine base editors with reduced off-target effects
|
|
CN112011576A
(zh)
*
|
2019-05-31 |
2020-12-01 |
华东师范大学 |
Crispr基因编辑技术在治疗地中海贫血中的应用
|
|
US12435330B2
(en)
|
2019-10-10 |
2025-10-07 |
The Broad Institute, Inc. |
Methods and compositions for prime editing RNA
|
|
CN112979823B
(zh)
*
|
2019-12-18 |
2022-04-08 |
华东师范大学 |
一种用于治疗和/或预防β血红蛋白病的产品及融合蛋白
|
|
WO2021226558A1
(en)
|
2020-05-08 |
2021-11-11 |
The Broad Institute, Inc. |
Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
|
|
CN111876416B
(zh)
*
|
2020-07-01 |
2021-09-03 |
广州瑞风生物科技有限公司 |
激活γ-珠蛋白基因表达的方法和组合物
|
|
EP4409004A1
(en)
*
|
2021-11-02 |
2024-08-07 |
The University of British Columbia |
Compositions and methods for preventing, ameliorating, or treating sickle cell disease
|
|
CN114848851A
(zh)
*
|
2022-04-29 |
2022-08-05 |
广州医科大学附属第三医院（广州重症孕产妇救治中心、广州柔济医院） |
治疗β-地中海贫血的药物
|
|
WO2024073751A1
(en)
|
2022-09-29 |
2024-04-04 |
Vor Biopharma Inc. |
Methods and compositions for gene modification and enrichment
|
|
WO2025038164A1
(en)
*
|
2023-08-15 |
2025-02-20 |
University Of Massachusetts |
Nick resection in cancer
|
|
WO2025128871A2
(en)
|
2023-12-13 |
2025-06-19 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|
|
WO2025174765A1
(en)
|
2024-02-12 |
2025-08-21 |
Renagade Therapeutics Management Inc. |
Lipid nanoparticles comprising coding rna molecules for use in gene editing and as vaccines and therapeutic agents
|